Oosten Liesbeth E M, Blokland Els, Kester Michel G D, Falkenburg J H Frederik, van Halteren Astrid G S, Goulmy Els
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Biol Blood Marrow Transplant. 2007 Feb;13(2):151-63. doi: 10.1016/j.bbmt.2006.10.025.
Hematopoietic system-specific miHAs are ideal targets for adoptive immunotherapy after allogeneic HLA (alloHLA)-matched SCT. Adoptive immunotherapy with cytotoxic T cells targeting hematopoietic system-specific miHAs restricted by alloHLA molecules is an attractive strategy to treat relapsed hematologic malignancies after HLA-mismatched SCT. As a proof of principle, we exploited 2 new strategies to generate alloHLA-A2-restricted miHA-specific T cells from HLA-A2(neg) donors using a HLA/miHA multimer-guided approach. In one strategy, autologous DCs coated with HLA-A2/miHA complexes were used for in vitro generation of miHA-specific T cells from HLA-A2(neg) male donors. In the other strategy, miHA-specific T cells were directly isolated from the peripheral blood of HLA-A2(neg) parous females with HLA-A2(pos) offspring. Both methods introduced recombinant HLA-A2/miHA complexes as the sole allogeneic target antigen. However, neither method yielded high avidity miHA-specific T cells or prevented the emergence of peptide-dependent promiscuous T cells. The latter T cells resembled miHA-specific T cells so closely with regard to tetramer binding and cytokine production that only extensive testing at a clonal level revealed their nonspecific nature. Therefore, promiscuity of the alloHLA-A2 T cell repertoire of HLA-A2(neg) individuals hampers in vitro generation of genuine miHA-specific T cells and limits its use for adoptive immunotherapy after HLA-A2 mismatched SCT.
造血系统特异性微小组织相容性抗原(miHAs)是异基因人类白细胞抗原(alloHLA)匹配的造血干细胞移植(SCT)后过继性免疫治疗的理想靶点。采用靶向受alloHLA分子限制的造血系统特异性miHAs的细胞毒性T细胞进行过继性免疫治疗,是治疗HLA不匹配的SCT后复发血液系统恶性肿瘤的一种有吸引力的策略。作为原理验证,我们利用两种新策略,采用HLA/miHA多聚体引导的方法,从HLA - A2阴性供体中产生alloHLA - A2限制的miHA特异性T细胞。在一种策略中,用HLA - A2/miHA复合物包被的自体树突状细胞(DCs)用于从HLA - A2阴性男性供体体外产生miHA特异性T细胞。在另一种策略中,从有HLA - A2阳性后代的HLA - A2阴性经产妇的外周血中直接分离miHA特异性T细胞。两种方法都引入重组HLA - A2/miHA复合物作为唯一的同种异体靶抗原。然而,两种方法都没有产生高亲和力的miHA特异性T细胞,也没有阻止肽依赖性混杂T细胞的出现。后一种T细胞在四聚体结合和细胞因子产生方面与miHA特异性T细胞非常相似,以至于只有在克隆水平进行广泛检测才能揭示其非特异性性质。因此,HLA - A2阴性个体的alloHLA - A2 T细胞库的混杂性阻碍了真正的miHA特异性T细胞的体外产生,并限制了其在HLA - A2不匹配的SCT后过继性免疫治疗中的应用。